Industry Trends

Mark Bouch, Stephen Bungay, and David Roblin outline how the technique of "mission command", a military approach to setting direction and executing strategy in the pharmaceutical industry, has developed over the last ten years.

With our latest review indicating declines in shareholder value and shareholder value to sales, those companies that score well in critical profit management metrics such as return on invested capital are best positioned to maintain that crucial edge in performance execution.

Our latest review reveals that those companies scoring well on profit management metrics are best positioned to maintain that crucial edge in performance execution.

Maiko Midena discusses the key fundamentals to success when it comes to forecasting with large multinational pharmaceutical organizations.

Pharm Exec's 17th annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.

Intellectual property analysis of one recently approved drug shows how Valiant might have missed out on at least one vital acquisition opportunity. Duncan Clark reports.

Bob Swindell explains how Greater Fort Lauderdale has spent the past few years quietly assembling one of the most dynamic pharmaceutical clusters in the country.

With this year marking our 11th installment, we look back on Pharm Exec's first 10 Brands of the Year-why they were chosen and the challenges, changes, and successes since.

Pharm Exec's Editorial Advisory Board member, Peter Young, cover a summary of the strategic issues facing the biopharma industry, but goes on to tell the story of what happened last year and this first quarter in terms of the stock market, M&A and financing (including IPOs) activity, where it is headed, and the implications for senior management.

The populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.

With the soaring valuations of companies in the public and M&A markets now seemingly a distant memory, the challenge for pharma and biotech business will be choosing just the right overall mix of M&A, licensing, and partnering.

For ethical pharma companies, there continues to be a wide variety of tools to acquire revenues and pipeline drugs, but the valuations are challenging, writes Peter Young.

How the need for biopharma innovation extends to questions around executive compensation.

Big pharma has become increasingly vulnerable to larger geopolitical and macroeconomic risks-a realization that has slowly creeped into their business planning.

As market headwinds persist, our latest industry review of shareholder value reveals a sharp performance differential between companies that pursue a strategy of specialized therapeutic focus and those that continue to rely on line diversity, size and scale.

With our annual Industry Audit marking its 15th year, we decided to compare 2002 approaches in boosting shareholder value to those of today. The fall in one particular performance metric is telling.

George Sillup and Stephen J. Porth identify the “hot button” issues attracting media attention in 2015.

Pharm Exec adds up some interesting figures from recent industry news.

Biopharma’s diversity commitment remains a work in progress but the benefits-in measurable ROI-are increasingly clear.

Do recent trends in the pharma and biotech M&A and equity markets signal a temporary lull - or a permanent drop? Peter Young reports.

Pharm Exec Editorial Advisory Board member Cliff Kalb poses some of the pertinent questions he expects the pharma industry will be asking this year.

A new discipline-population health-contests disease treatment as an end in itself. It asks: besides advancing the science of medicine, what do biopharmaceuticals actually do to improve health overall?

As tech giants, enter the life sciences industry, healthcare companies should adapt their business model and embark with these new players on a more ambitious, personalized, and preventive healthcare strategy.

In the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.

With hostile takeovers on the rise, Mike Straw argues that pharma boards have a huge role to play in managing the people issues.

Driven by knowledge advances and the importance of a more collaborative commercial model, intellectual property (IP) has morphed from an arcane, specialized function dominated by technicians to a showcase strategic priority of the “c-suite.” This trend is hardly restricted to the life sciences. In fact, some of the most creative work in using IP tools to extract more value from knowledge assets is taking place among businesses that operate across multiple sectors.

After a sharp spike in revenues, this year’s audit finds our 25 companies doubling down to secure the operational efficiencies that promise to better align with an increasingly tightfisted payer community. Never before has market relevance been so firmly linked to customer reputation.

A closer look at our Industry Audit numbers hints to a clear divide between two alternative strategies for long-term growth: scale versus focus.

New cell-culture techniques, biomanufacturing formats, and the expansion of single-use applications are driving rapid change in the biopharma market.

 Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others.